DAIC

MARCH 13, 2024

CMS previously published a New Technology APC (Ambulatory Payment Classifications) code that covers the CardiAMP Cell Therapy investigational study procedure, including the BioCardia investigational products utilized to perform the study procedure, allowing the study centers to be reimbursed for the study procedure and products.

CMS 111

CMS Heart Failure Reimbursement Quality of Life 111

DAIC

FEBRUARY 14, 2024

Recent shifts in third-party payer reimbursement, led by the Centers for Medicare and Medicaid , have resulted in continued trends of minimally invasive cardiac procedures on stable patients increasingly being performed outside of a hospital setting.

Outpatient 105

Outpatient Hospital Reimbursement Medicaid 105

DAIC

JULY 25, 2024

The CardiAMP clinical development for heart failure is supported by the Maryland Stem Cell Research Fund and is reimbursed by Center for Medicare and Medicaid Services (CMS) for both treatment and control procedures. CAUTION - Limited by United States law to investigational use.

Heart Failure 111

Heart Failure Quality of Life CMS Reimbursement 111

GEMMS

APRIL 8, 2024

In addition to this, the Medicaid EHR Incentive Program aims to encourage healthcare providers to adopt and effectively use certified Health IT to improve patient care information exchange. Contact us today to schedule a demo to take the first step towards optimizing your MIPS reporting and improving outcomes for your patients.

Medicare 52

Medicare Innovation Medicaid Patient Care 52

The Beat Blog

JUNE 9, 2022

Programs receive a set amount monthly from Medicare and Medicaid to provide nearly everything for people over 55 whose needs qualify them for a nursing home but who don’t want to enter one. This may allow the PACE plan to adjust risk scores and potentially increase reimbursement per participant.

Reimbursement 52

Reimbursement Medicaid Medicare Nursing 52

DAIC

MARCH 7, 2024

Despite improvements with current medications and devices, heart failure remains at epidemic proportions and we now have an exciting opportunity for a therapy to improve important, objective outcomes, such as mortality and hospital re-admissions rates. “We The CardiAMP HF II trial is expected to similarly secure CMS reimbursement.

Heart Failure 105

Heart Failure Biomarkers CMS Reimbursement 105